admin,
January 2016
January 2016 With a now $AUD50bn market cap, CSL has grown strongly over many years, benefiting from ongoing demand growth for its mainstay plasma products. At the same time, CSL has invested heavily in research and development (R&D), for both its mainstay blood plasma products, but also ‘specialty’ products for niche diseases, flu vaccines and…